Company Description
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States.
The company’s lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma.
It is also developing IMNN-101, a COVID-19 booster vaccine that has completed a Phase 1 clinical trial.
In addition, the company develops non-viral DNA technology across modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; and PlaCCine for the coding of viral antigens that can elicit a strong immunological response.
The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022.
Imunon, Inc. was incorporated in 1982 and is headquartered in Lawrenceville, New Jersey.
| Country | United States |
| Founded | 1982 |
| IPO Date | Mar 5, 1985 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 20 |
| CEO | Stacy Lindborg |
Contact Details
Address: 997 Lenox Drive, Suite 100 Lawrenceville, New Jersey 08648 United States | |
| Phone | 609 896 9100 |
| Website | imunon.com |
Stock Details
| Ticker Symbol | IMNN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000749647 |
| CUSIP Number | 15117N701 |
| ISIN Number | US15117N7012 |
| Employer ID | 52-1256615 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Michael H. Tardugno | Executive Chairman |
| Dr. Douglas V. Faller M.D., Ph.D. | Chief Medical Officer |
| Kristin Longobardi M.B.A. | Senior Vice President of Strategic Operations |
| Dr. Stephen G. Machatha Ph.D. | Senior Vice President of Technical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 28, 2026 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Oct 27, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Oct 27, 2026 | 8-K | Current Report |
| Oct 21, 2026 | 8-K | Current Report |
| Oct 13, 2026 | DRS | [Cover] Draft Registration Statement |
| Sep 29, 2026 | 8-K | Current Report |
| Aug 14, 2026 | SCHEDULE 13G/A | Filing |
| Aug 11, 2026 | 8-K | Current Report |
| Aug 11, 2026 | 10-Q | Quarterly Report |
| Aug 11, 2026 | 8-K | Current Report |